Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Cyclophosphamide 2043 Radiotherapy 1859 Cisplatin 1826 Carboplatin 1533 Gemcitabine 1435 Paclitaxel 1291 Bevacizumab 1271 Docetaxel 1202 pembrolizumab 1201 Oxaliplatin 1160 Capecitabine 1145 Fluorouracil 1061 Dexamethasone 971 Rituximab 919 Nivolumab 908 Magnetic Resonance Spectroscopy 864 Etoposide 839 Doxorubicin 823 Drug Therapy 792 Radiosurgery 776 Irinotecan 775 Cytarabine 736 fludarabine 716 Leucovorin 676 Lenalidomide 609 fludarabine phosphate 564 Temozolomide 552 Radiation 541 Filgrastim 540 Cetuximab 537

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Interventional × DLL3 protein, human × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡